Introduction
Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all lung malignancies and remains the leading cause of cancer-related mortality worldwide. Driven by advances in molecular pathology, next-generation sequencing (NGS), and precision oncology, the management of NSCLC has been fundamentally transformed over the past decade. This narrative review synthesizes current global epidemiologic data, clinically actionable molecular subtype distributions, diagnostic testing standards, and stage-based treatment paradigms for oncologists, pulmonologists, pathologists, epidemiologists, and clinical researchers.
1. Global Disease Burden and Epidemiologic Trends
In 2022, lung cancer was the most frequently diagnosed cancer globally and the leading cause of cancer death, with an estimated 2.48 million new cases (12.4% of all incident cancers) and 1.82 million deaths (18.7% of all cancer deaths) 116. NSCLC accounts for the vast majority of this burden. Projections indicate that if current rates remain stable, global lung cancer burden will increase to 4.62 million new cases and 3.55 million deaths annually by 2050—an 86.2% and 95% rise respectively—driven primarily by population aging and demographic growth 12.
Smoking remains the dominant attributable risk factor, responsible for 60–70% of cases in men and a substantial proportion in women, though the fraction attributable to occupational exposures, ambient particulate matter, household air pollution from solid fuels, and secondhand smoke is increasing, particularly in lower sociodemographic index (SDI) regions and among women 4. The Global Burden of Disease Study 2021 demonstrated that while age-standardized incidence rates (ASIR) declined modestly at an average annual percent change (AAPC) of −0.3% from 1992 to 2021 in high-income countries (driven by tobacco control), age-standardized mortality rates (ASMR) in females are increasing, reflecting rising female smoking prevalence and environmental exposures 3.
Table 1. NSCLC Global Incidence and Mortality by Key Region (GLOBOCAN 2022)
| Region / Country | New Cases (2022) | ASR Incidence (per 100,000) | Deaths (2022) | ASR Mortality (per 100,000) |
|---|---|---|---|---|
| Global (all) | 2,480,675 | 32.1 (M) / 16.2 (F) | 1,820,000 | 24.8 (M) / 9.8 (F) |
| China | 1,060,584 | 40.8 | 733,291 | 26.7 |
| USA | 226,033 | 31.9 | 127,653 | 16.6 |
| Japan | 136,723 | 30.5 | 83,243 | 14.2 |
| Hungary | Highest national ASR | 47.6 | — | — |
| Serbia | High ASR | 40.4 | — | — |
| Eastern Asia (regional) | Highest regional ASIR | 39.4 | — | 25.1 |
| Africa (most sub-regions) | Low burden | <4.0 | — | Low |
ASR = age-standardized rate; M = male; F = female 212
Sex-based disparities are pronounced: 1,572,045 cases occurred in men versus 908,630 in women globally in 2022, with the highest male incidence rates recorded in Turkey (ASR 68.0), Hungary (ASR 64.4), and Serbia (ASR 59.6), while female incidence is highest in Hungary (ASR 35.0), Denmark (ASR 34.4), and the Netherlands (ASR 33.9) 2. A very high Human Development Index (HDI) correlates with higher ASIRs—very high and high HDI countries account for over 90% of global cases—though this reflects historical smoking prevalence and superior diagnostic capacity rather than intrinsic risk 12.
2. Histologic and Molecular Subtype Distribution
Adenocarcinoma has become the globally predominant NSCLC subtype, particularly in developed nations, among never-smokers, and in East Asian populations. Squamous cell carcinoma (SqCC) remains more prevalent in heavy smokers and in certain geographic regions. Large-cell carcinoma and other NSCLC variants constitute a smaller proportion. Clinically actionable molecular alterations vary markedly by geography, histology, and smoking status.
Table 2. Major Actionable Molecular Alterations in NSCLC Adenocarcinoma: Prevalence and Clinical Implications
| Alteration | Prevalence (Global) | East Asian (Adenocarcinoma) | Western (Adenocarcinoma) | Key Approved Therapies | Clinical Notes |
|---|---|---|---|---|---|
| EGFR mutation (19del, L858R) | 10–50% | 40–50% | 10–15% | Erlotinib, gefitinib, afatinib, osimertinib, lazertinib, aumolertinib | Most common actionable driver; highest in East Asia, never-smokers, women |
| EGFR exon 20 insertion | 5–10% of EGFR+ | Similar | Similar | Amivantamab, sunvozertinib | Limited TKI sensitivity; distinct therapeutic challenge |
| KRAS G12C | ~13% of adenocarcinoma | Lower | Higher (~25–35% KRAS-mutant) | Sotorasib, adagrasib, fulzerasib, glecirasib | Higher PD-L1 expression; prior "undruggable" target now actionable |
| ALK rearrangement | 3–7% | 3–7% | 2–3% | Crizotinib, alectinib, brigatinib, lorlatinib, ceritinib, ensartinib | CNS-active next-generation inhibitors preferred |
| ROS1 fusion | 1–2% | ~2% | ~1% | Crizotinib, entrectinib, repotrectinib, taletrectinib | Overlap with ALK biology; next-generation options available |
| BRAF V600E | 1–3% | ~1% | 1–3% | Dabrafenib + trametinib, encorafenib | BRAF/MEK inhibitor combination preferred |
| MET exon 14 skipping | 3–4% | Similar | Similar | Capmatinib, tepotinib, savolitinib, gumarontinib | Enriched in older, never-smoking patients |
| RET fusion | 1–2% | Similar | Similar | Selpercatinib, pralsetinib | Selective RET inhibitors demonstrate high response rates |
| NTRK rearrangement | <1% | Similar | Similar | Larotrectinib, entrectinib, repotrectinib | Rare but highly actionable; tumor-agnostic approvals |
| HER2 mutation/amplification | 2–5% | Higher HER2 mutation rate | ~2–3% | Trastuzumab deruxtecan, trastuzumab rezetecan | ADCs increasingly preferred over TKIs |
| PD-L1 expression (TPS ≥50%) | ~30% | Lower in EGFR+ (~4.6%) | Higher in KRAS+ (~22.5%) | Pembrolizumab, atezolizumab, cemiplimab | Critical for ICI eligibility in driver-negative disease |
TPS = tumor proportion score; ADC = antibody-drug conjugate; ICI = immune checkpoint inhibitor; TKI = tyrosine kinase inhibitor 571315
KRAS mutations overall occur in approximately 30% of lung adenocarcinomas, with KRAS G12C comprising ~44% of KRAS alterations 7. Notably, a Chinese cohort study confirmed that PD-L1 positivity is substantially lower in EGFR-mutant (18.8% at TPS ≥1%) versus KRAS-mutant tumors (47.3% at TPS ≥1%), with important implications for immunotherapy sequencing 13. Geographic heterogeneity in molecular profiles is illustrated further by a Southwest China registry, which documented higher EGFR compound mutations (G719X + S768I; G719X + L861Q) and markedly higher KRAS G12C prevalence compared with other Yunnan regions, emphasizing the need for region-specific diagnostic strategies 8.
3. Diagnostic and Biomarker Testing Landscape
Comprehensive molecular testing is now standard of care for all advanced NSCLC and increasingly recommended from stage III onward. NGS is the preferred platform, enabling simultaneous detection of single-nucleotide variants, insertions/deletions, copy-number variations, and gene fusions across EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, HER2, KRAS, and emerging targets 14. Immunohistochemistry (IHC) for PD-L1 (tumor proportion score [TPS]) and for ALK/ROS1 screening, and fluorescence in situ hybridization (FISH) for definitive ALK/ROS1 confirmation, remain integral adjuncts, particularly in resource-limited settings 14.
Real-world data from the German CRISP registry (n = 3,717 advanced NSCLC patients) documented testing rates of 92.2% in non-squamous versus 70.7% in squamous histology; biomarker-specific rates for EGFR, ALK, ROS1, and BRAF were 72.5%, 74.5%, 66.1%, and 53.0%, respectively, in non-squamous disease 6. PD-L1 testing was performed in 64.5% of non-squamous and 58.5% of squamous cases. Despite improvements from 83.2% (2015/16) to 94.2% (2019), a significant minority remained untested—representing missed opportunities for precision oncology 6.
Cytological samples obtained via endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and esophageal ultrasound-guided fine needle aspiration (EUS-B-FNA) have been validated for molecular profiling, with individual gene success rates of 85–97% for EGFR, KRAS, ALK, and ROS1 in prospective studies 11. Liquid biopsy using circulating tumor DNA (ctDNA) has gained traction as a complementary approach, particularly for re-testing at disease progression to identify acquired resistance mutations (e.g., EGFR T790M) and for minimal residual disease (MRD) monitoring post-resection 14. However, tissue biopsy with adequate tumor cellularity (≥20% tumor nuclei) remains the gold standard 14. Significant access disparities persist in low- and middle-income countries (LMICs), where limited NGS infrastructure, insufficient tissue specimens, and high costs restrict molecular testing implementation 12.
4. Current Treatment Landscape
Treatment selection in NSCLC is determined by stage, molecular driver status, PD-L1 expression, histology, and performance status.
Table 3. Stage-Based NSCLC Treatment Standards (NCCN 2025–2026, ESMO, CSCO 2025)
| Stage / Setting | Primary Treatment | Molecular/PD-L1 Considerations | Key Agents / Approaches |
|---|---|---|---|
| Early-stage resectable (I–IIIA) | Surgical resection (lobectomy or segmentectomy); SBRT for inoperable patients | Emerging adjuvant targeted therapy (EGFR TKI); adjuvant ICI for high-risk | Cisplatin doublets; atezolizumab, durvalumab (adjuvant); osimertinib (EGFR-mutant adjuvant) |
| Locally advanced unresectable (III) | Concurrent chemoradiotherapy (CCRT) ± sequential chemotherapy | EGFR/ALK-mutant: targeted therapy sequencing; PD-L1 ≥1%: consolidation durvalumab | Platinum + etoposide/taxane + RT; durvalumab consolidation (PACIFIC strategy); osimertinib (EGFR-mutant, LAURA trial: mPFS 39.1 vs. 5.6 months) |
| Metastatic (IV), driver-mutant | First-line targeted TKI monotherapy | Mutation-specific TKI selection; sequential agents at progression | EGFR: osimertinib, lazertinib, aumolertinib; ALK: alectinib, lorlatinib; ROS1: entrectinib, repotrectinib; BRAF: dabrafenib + trametinib; MET: tepotinib, capmatinib; RET: selpercatinib; KRAS G12C: sotorasib, adagrasib, fulzerasib; HER2: trastuzumab deruxtecan; NTRK: larotrectinib, entrectinib |
| Metastatic (IV), wild-type, PD-L1 ≥50% | Single-agent PD-1/PD-L1 inhibitor | PD-L1 TPS guides monotherapy vs. combination | Pembrolizumab, atezolizumab, cemiplimab |
| Metastatic (IV), wild-type, PD-L1 <50% | Platinum-doublet chemotherapy + ICI | Histology-specific doublet selection; pemetrexed for non-squamous | Carboplatin/cisplatin + pemetrexed or paclitaxel ± pembrolizumab/atezolizumab/tislelizumab |
| Squamous NSCLC (any PD-L1) | Platinum-doublet ± ICI | PD-L1 guides ICI addition; EGFR/ALK testing not routinely recommended | Carboplatin + paclitaxel/nab-paclitaxel ± ICI |
mPFS = median progression-free survival; RT = radiotherapy; SBRT = stereotactic body radiotherapy 115161718
In locally advanced disease, the LAURA trial demonstrated that osimertinib after chemoradiotherapy in unresectable stage III EGFR-mutated NSCLC achieved a median progression-free survival of 39.1 months versus 5.6 months with placebo (hazard ratio 0.16; 95% CI 0.10–0.24), with 74% of patients alive and progression-free at 12 months 1. In the metastatic setting, real-world French cohort data (ESME database, n = 10,177) confirm that KRAS-mutant patients have poorer outcomes versus wild-type (first-line median PFS: 4.0 vs. 5.1 months; OS: 12.6 vs. 15.4 months), though KRAS G12C-mutant patients derive superior benefit from first-line chemoimmunotherapy (median OS 48.8 months) 9.
The treatment pipeline is expanding rapidly, particularly in bispecific antibodies (e.g., ivonescimab combining PD-1 and VEGF blockade), antibody-drug conjugates (telisotuzumab vedotin for MET-overexpressing NSCLC received FDA approval in May 2025), and next-generation KRAS inhibitors (olomorasib, divarasib, garsorasib) in both the USA and China 15. China demonstrates especially dense domestic innovation across EGFR (aumolertinib, firmonertinib, befortinib), ALK/ROS1 (iruplinalkib, envonalkib, taletrectinib), KRAS (fulzerasib, glecirasib), and PD-1/PD-L1 (tislelizumab, camrelizumab, sintilimab) therapeutic categories 15.
5. Unmet Needs and Future Directions
Despite transformative advances, major challenges persist. Late-stage diagnosis at presentation remains the foremost barrier to curative intent therapy, particularly in LMICs and in populations without access to low-dose computed tomography (CT) screening programs. Low-dose CT screening is recommended for defined high-risk individuals (current or former heavy smokers) in well-resourced health systems and has demonstrated mortality reduction, yet implementation remains globally inconsistent 1. Acquired resistance to targeted therapies—mediated by EGFR T790M, MET amplification, and bypass pathway activation—necessitates serial molecular profiling at progression. Immunotherapy non-response in EGFR-mutant and other driver-mutant populations underscores the need for combination strategies and refined biomarker-based patient selection 13. Brain metastases (occurring in 10–30% of patients) require CNS-penetrant agents and integrated imaging surveillance 16.
Emerging strategies to address these challenges include: broader ctDNA-based MRD monitoring post-resection to guide adjuvant therapy decisions; integration of multi-omic liquid biopsy panels for early resistance detection; development of next-generation TKIs with improved resistance coverage and CNS activity; combination regimens incorporating TKI plus chemotherapy or immunotherapy; and equitable global expansion of NGS-based molecular testing. The pronounced gap in biomarker testing access between high-income and low-income settings—and the unmet need in squamous histology (where 57.9% of patients harbor no actionable mutation in real-world registries) 6—represent critical public health priorities for the coming decade.
Conclusion
NSCLC remains a global health emergency, with 2.48 million incident cases and 1.82 million deaths annually and projections indicating continued escalation through 2050. Molecular profiling has transformed care, enabling precision treatment for EGFR-, ALK-, ROS1-, BRAF-, MET-, RET-, NTRK-, HER2-, and KRAS-defined subsets. Geographic disparities in molecular profiles, access to NGS, and availability of novel therapeutics necessitate population-specific diagnostic algorithms and concerted international efforts to close equity gaps. Continued integration of advanced diagnostics, combination regimens, and next-generation targeted agents—alongside public health investment in tobacco control, environmental regulation, and low-dose CT screening—offers the most credible path toward reducing NSCLC mortality at the global level.